GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia

Glucagon-like peptide-1 receptor agonists and dual GLP-1/GIP agonists are associated with a high incidence of gastrointestinal adverse events.

• Common gastrointestinal issues include dyspepsia and symptoms resembling gastroparesis.
• Most gastrointestinal effects are transient, but a notable number of patients experience persistent intolerance.
• Persistent gastrointestinal symptoms can lead to misdiagnosis and unnecessary medical procedures.
• Current treatment guidelines provide limited support for managing symptoms in patients with these adverse events.
• There is a need for structured strategies to improve management, including risk stratification and tailored dose adjustments.

AI simplified